SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) August 9, 2004
CollaGenex Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 0-28308 | 52-1758016 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 41 University Drive, Newtown, Pennsylvania | 18940 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(215) 579-7388
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On August 11, 2004, CollaGenex Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing that in accordance with NASDAQ Marketplace Rule 4350, as amended, the Company granted inducement stock options to Greg Ford, the Company’s Vice President, Business Development and Strategic Planning, and Brad Zerler, the Company’s Vice President of Research, in connection with the commencement of their employment with the Company. These options were granted without stockholder approval pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) under the following terms: 70,000 non-qualified stock options to Mr. Ford and 40,000 non-qualified stock options to Mr. Zerler, each with exercise prices equal to the fair market value on the grant date, ten-year duration and vesting at the rate of 20% for each year of service with the Company.
The foregoing statements are qualified in their entirety by the Company’s press release, a complete copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements,Pro Forma Financial Information and Exhibits.
| (c) | Exhibits. |
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 11, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
COLLAGENEX PHARMACEUTICALS, INC. | ||||
| By: | /S/ NANCY C. BROADBENT | |||
Nancy C. Broadbent | ||||
Chief Financial Officer | ||||
(Principal Financial Officer) | ||||
Date: August 11, 2004
